ACHIEVE LIFE SCIENCES INC
ACHVNASDAQTrading Snapshot
- Day Range
- $6.57 – $6.72
- 52-Week Range
- $2.37 – $7.11
- Volume
- $2.84B
- Avg Volume
- $2.57B
- Shares Outstanding
- 102.7M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $18M
- Last Q Revenue
- $4M
- P/E Ratio
- —
- P/S Ratio
- 38.4x
- EPS (TTM)
- $-1.11
- Dividend Yield
- —
Why Investors Own ACHV
- ✓High-growth profile — revenue up +55.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ACHIEVE LIFE SCIENCES INC
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Achieve Life Sciences Q2 EPS $(0.80) Misses $(0.16) Estimate
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.16) by 400 percent. This is a 116.22 percent decrease over losses of $(0.37) per
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales guidance. Other stocks also down in pre-market.